Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page
- Check6 days agoChange DetectedNew quick-access links were added on the study details page, including 'Check who can join', 'Find Contact Information', 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and the version label was updated from v3.5.5 to v3.6.0 with a formatting change from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.2%

- Check14 days agoChange DetectedNew study locations were added: Tampa, Florida, USA; Antofagasta, Chile (1270244); and Seoul Teugbyeolsi, South Korea (03080) with new site contacts Luis Barra (Site 6003) and Sergio Gloger Kojchen (Site 6002). Older site entries and identifiers were removed or updated (e.g., Tampa 33614-2846, Antofagasta 127-0244, Site 6002/6003 references), and the revision label was updated to v3.5.5.SummaryDifference0.6%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a new version of the page. This represents a minor update to the page's documentation/history rather than substantive changes to the study information.SummaryDifference0.0%

- Check36 days agoChange DetectedEnrollment status updated to Completed on 2026-05-11, replacing the prior Active, not recruiting status. This signals that the study has finished enrolling participants and is moving toward completion and results submission.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded a Tampa, Florida site (33614-2846) with status Completed. Removed a Tampa site (33614-2869) that was Active, not recruiting, reflecting a change in recruitment status at that location.SummaryDifference0.1%

- Check50 days agoChange DetectedThis update expands the number of locations from 119 to 154 by adding numerous sites across multiple countries, including the UK, Switzerland, Poland, Peru, Chile, China, and more. It reflects a broader recruitment footprint across the study network.SummaryDifference8%

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.